Bruce Evan Johnson
Impact in
- Oncology top 0.01%
- Lung Cancer Research Studies
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Papers in
-
- Lung Cancer Treatments and Mutations 162
- Lung Cancer Diagnosis and Treatment 35
- Oncology 168
- Lung Cancer Research Studies 80
- HER2/EGFR in Cancer Research 21
- Colorectal Cancer Treatments and Studies 21
- Cancer Immunotherapy and Biomarkers 21
- Co-authors
- Pasi Antero Janne (75 shared papers)Matthew Meyerson (18 shared papers)Neal Ian Lindeman (18 shared papers)Michael J. Eck (4 shared papers)Titus J. Boggon (3 shared papers)David Michael Jackman (30 shared papers)Sean I. Tracy (3 shared papers)Jeffrey A. Engelman (11 shared papers)
- Journals
- Clinical Cancer Research (41 papers)Journal of Clinical Oncology (34 papers)Journal of Thoracic Oncology (29 papers)Lung Cancer (21 papers)Cancer (19 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Bruce Evan Johnson
407 papers receiving 68.2k citations
Bruce Evan Johnson's Hit Papers
Peers
Comparison fields: 5 of 195
- Oncology 30.2k
- Pulmonary and Respiratory Medicine 32.2k
- Cancer Research 12.6k
- Molecular Biology 25.5k
- Pathology and Forensic Medicine 4.4k
Countries citing papers authored by Bruce Evan Johnson
This map shows the geographic impact of Bruce Evan Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce Evan Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce Evan Johnson more than expected).
Fields of papers citing papers by Bruce Evan Johnson
This network shows the impact of papers produced by Bruce Evan Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce Evan Johnson. The network helps show where Bruce Evan Johnson may publish in the future.
Co-authors
The 25 scholars most cited alongside Bruce Evan Johnson, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 425 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy Hit paper breakdown → | 2004 | 8145 |
| 2 | MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling Hit paper breakdown → | 2007 | 3890 |
| 3 | EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib Hit paper breakdown → | 2005 | 3445 |
| 4 | A Cell Cycle Regulator Potentially Involved in Genesis of Many Tumor Types Hit paper breakdown → | 1994 | 2443 |
| 5 | Somatic mutations affect key pathways in lung adenocarcinoma Hit paper breakdown → | 2008 | 2237 |
| 6 | Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses Hit paper breakdown → | 2001 | 2120 |
| 7 | Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing Hit paper breakdown → | 2012 | 1516 |
| 8 | Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs Hit paper breakdown → | 2014 | 1428 |
| 9 | Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission Hit paper breakdown → | 1999 | 1329 |
| 10 | Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints Hit paper breakdown → | 2016 | 1314 |
| 11 | TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2005 | 1284 |
| 12 | Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib Hit paper breakdown → | 2005 | 1273 |
| 13 | Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial Hit paper breakdown → | 2017 | 1093 |
| 14 | A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade Hit paper breakdown → | 2018 | 1015 |
| 15 | Characterizing the cancer genome in lung adenocarcinoma Hit paper breakdown → | 2007 | 924 |
| 16 | LKB1 modulates lung cancer differentiation and metastasis Hit paper breakdown → | 2007 | 868 |
| 17 | Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets Hit paper breakdown → | 2015 | 849 |
| 18 | First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring Somatic EGFR Mutations Hit paper breakdown → | 2008 | 726 |
| 19 | Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial Hit paper breakdown → | 2016 | 706 |
| 20 | The BATTLE Trial: Personalizing Therapy for Lung Cancer Hit paper breakdown → | 2011 | 702 |
About Bruce Evan Johnson
Bruce Evan Johnson is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Molecular Biology and Epidemiology, having authored 425 papers that have together received 70.7k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (162 papers), Lung Cancer Research Studies (80 papers), Cancer Genomics and Diagnostics (42 papers), Lung Cancer Diagnosis and Treatment (35 papers), Neuroendocrine Tumor Research Advances (34 papers), HER2/EGFR in Cancer Research (21 papers), Colorectal Cancer Treatments and Studies (21 papers) and Cancer Immunotherapy and Biomarkers (21 papers). The work is most often cited by research in Oncology (30.2k citations), Pulmonary and Respiratory Medicine (32.2k citations), Cancer Research (12.6k citations), Molecular Biology (25.5k citations) and Pathology and Forensic Medicine (4.4k citations). Bruce Evan Johnson has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Pasi Antero Janne, Matthew Meyerson, Neal Ian Lindeman, Michael J. Eck, Titus J. Boggon, David Michael Jackman, Sean I. Tracy, Jeffrey A. Engelman, Jeffrey C. Lee and Katsuhiko Naoki. Their work appears in journals such as Clinical Cancer Research, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.